Drug Profile
Donepezil - Dongkook Pharmaceutical
Alternative Names: DKF-310Latest Information Update: 02 Sep 2022
Price :
$50
*
At a glance
- Originator Dongkook
- Developer Dongkook Pharmaceutical
- Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dementia
- No development reported Alzheimer's disease
Most Recent Events
- 02 Sep 2022 Preclinical trials in Dementia in South Korea (IM) (Dongkook Pharmaceutical pipeline, September 2022)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in South Korea (IM, Injection)
- 23 Mar 2016 Dongkook Pharmaceutical has patent protection for donepezil